GlassScriptPhysician profile
Gregory S Parsons
NPI 1326042110
$2,385.61
in general payments reported to CMS, 2019-2025
20 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Otolaryngic Allergy provider received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $852 · 2021: $262 · 2022: $68.41 · 2023: $298 · 2024: $381 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $678.55 | 2019-2025 | |
| Optinose US, INC. | $343.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $267.77 | 2019-2025 | Tezspire |
| Integra Lifesciences Corporation | $164.78 | 2024 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
| Alk-Abello, INC | $138.64 | 2019 | |
| Aerin Medical INC. | $128.24 | 2019-2024 | |
| Abbvie INC. | $124.84 | 2024-2025 | |
| Medtronic USA, INC. | $110.00 | 2019 | |
| Glaxosmithkline, LLC. | $86.32 | 2023 | Nucala |
| Regeneron Healthcare Solutions, INC. | $75.55 | 2019-2025 | Dupixent |
| Acclarent, INC | $65.64 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $59.63 | 2025 | Neffy |
| Biohaven Pharmaceutical Holding Company LTD. | $27.42 | 2022 | |
| Intersect Ent, INC. | $19.16 | 2021 | |
| Smith+Nephew, INC. | $17.16 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $16.29 | 2023 | Immunocap |
| Pfizer INC. | $16.24 | 2023 | |
| Cook Medical LLC | $15.73 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.46 | 2025 | Xhance |
| Hikma Pharmaceuticals USA | $14.94 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Parsons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.